These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

483 related items for PubMed ID: 19850869

  • 1. Differential induction of apoptosis in HER2 and EGFR addicted cancers following PI3K inhibition.
    Faber AC, Li D, Song Y, Liang MC, Yeap BY, Bronson RT, Lifshits E, Chen Z, Maira SM, García-Echeverría C, Wong KK, Engelman JA.
    Proc Natl Acad Sci U S A; 2009 Nov 17; 106(46):19503-8. PubMed ID: 19850869
    [Abstract] [Full Text] [Related]

  • 2. The dual PI3K/mTOR inhibitor BEZ235 restricts the growth of lung cancer tumors regardless of EGFR status, as a potent accompanist in combined therapeutic regimens.
    Wu YY, Wu HC, Wu JE, Huang KY, Yang SC, Chen SX, Tsao CJ, Hsu KF, Chen YL, Hong TM.
    J Exp Clin Cancer Res; 2019 Jul 01; 38(1):282. PubMed ID: 31262325
    [Abstract] [Full Text] [Related]

  • 3. Antitumor activity of selective MEK1/2 inhibitor AZD6244 in combination with PI3K/mTOR inhibitor BEZ235 in gefitinib-resistant NSCLC xenograft models.
    Qu Y, Wu X, Yin Y, Yang Y, Ma D, Li H.
    J Exp Clin Cancer Res; 2014 Jun 17; 33(1):52. PubMed ID: 24939055
    [Abstract] [Full Text] [Related]

  • 4. Combined inhibition of MEK and PI3K pathways overcomes acquired resistance to EGFR-TKIs in non-small cell lung cancer.
    Sato H, Yamamoto H, Sakaguchi M, Shien K, Tomida S, Shien T, Ikeda H, Hatono M, Torigoe H, Namba K, Yoshioka T, Kurihara E, Ogoshi Y, Takahashi Y, Soh J, Toyooka S.
    Cancer Sci; 2018 Oct 17; 109(10):3183-3196. PubMed ID: 30098066
    [Abstract] [Full Text] [Related]

  • 5. BIM mediates EGFR tyrosine kinase inhibitor-induced apoptosis in lung cancers with oncogenic EGFR mutations.
    Costa DB, Halmos B, Kumar A, Schumer ST, Huberman MS, Boggon TJ, Tenen DG, Kobayashi S.
    PLoS Med; 2007 Oct 17; 4(10):1669-79; discussion 1680. PubMed ID: 17973572
    [Abstract] [Full Text] [Related]

  • 6. The novel phosphoinositide 3-kinase-mammalian target of rapamycin inhibitor, BEZ235, circumvents erlotinib resistance of epidermal growth factor receptor mutant lung cancer cells triggered by hepatocyte growth factor.
    Sano T, Takeuchi S, Nakagawa T, Ishikawa D, Nanjo S, Yamada T, Nakamura T, Matsumoto K, Yano S.
    Int J Cancer; 2013 Jul 15; 133(2):505-13. PubMed ID: 23319394
    [Abstract] [Full Text] [Related]

  • 7. Polyphyllin II Restores Sensitization of the Resistance of PC-9/ZD Cells to Gefitinib by a Negative Regulation of the PI3K/Akt/mTOR Signaling Pathway.
    Zheng R, Jiang H, Li J, Liu X, Xu H.
    Curr Cancer Drug Targets; 2017 Jul 15; 17(4):376-385. PubMed ID: 28093061
    [Abstract] [Full Text] [Related]

  • 8. Acquired resistance to epidermal growth factor receptor tyrosine kinase inhibitors in non-small-cell lung cancers dependent on the epidermal growth factor receptor pathway.
    Nguyen KS, Kobayashi S, Costa DB.
    Clin Lung Cancer; 2009 Jul 15; 10(4):281-9. PubMed ID: 19632948
    [Abstract] [Full Text] [Related]

  • 9. Gefitinib-induced killing of NSCLC cell lines expressing mutant EGFR requires BIM and can be enhanced by BH3 mimetics.
    Cragg MS, Kuroda J, Puthalakath H, Huang DC, Strasser A.
    PLoS Med; 2007 Oct 15; 4(10):1681-89; discussion 1690. PubMed ID: 17973573
    [Abstract] [Full Text] [Related]

  • 10.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 11.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 12.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 13. Combination of BIBW2992 and ARQ 197 is effective against erlotinib-resistant human lung cancer cells with the EGFR T790M mutation.
    Qu G, Liu C, Sun B, Zhou C, Zhang Z, Wang P.
    Oncol Rep; 2014 Jul 15; 32(1):341-7. PubMed ID: 24842595
    [Abstract] [Full Text] [Related]

  • 14. Rapamycin synergizes with the epidermal growth factor receptor inhibitor erlotinib in non-small-cell lung, pancreatic, colon, and breast tumors.
    Buck E, Eyzaguirre A, Brown E, Petti F, McCormack S, Haley JD, Iwata KK, Gibson NW, Griffin G.
    Mol Cancer Ther; 2006 Nov 15; 5(11):2676-84. PubMed ID: 17121914
    [Abstract] [Full Text] [Related]

  • 15. BIM and mTOR expression levels predict outcome to erlotinib in EGFR-mutant non-small-cell lung cancer.
    Karachaliou N, Codony-Servat J, Teixidó C, Pilotto S, Drozdowskyj A, Codony-Servat C, Giménez-Capitán A, Molina-Vila MA, Bertrán-Alamillo J, Gervais R, Massuti B, Morán T, Majem M, Felip E, Carcereny E, García-Campelo R, Viteri S, González-Cao M, Morales-Espinosa D, Verlicchi A, Crisetti E, Chaib I, Santarpia M, Luis Ramírez J, Bosch-Barrera J, Felipe Cardona A, de Marinis F, López-Vivanco G, Miguel Sánchez J, Vergnenegre A, Sánchez Hernández JJ, Sperduti I, Bria E, Rosell R.
    Sci Rep; 2015 Dec 07; 5():17499. PubMed ID: 26639561
    [Abstract] [Full Text] [Related]

  • 16. Blocking the PI3K/AKT and MEK/ERK signaling pathways can overcome gefitinib-resistance in non-small cell lung cancer cell lines.
    Li H, Schmid-Bindert G, Wang D, Zhao Y, Yang X, Su B, Zhou C.
    Adv Med Sci; 2011 Dec 07; 56(2):275-84. PubMed ID: 22037177
    [Abstract] [Full Text] [Related]

  • 17. MEK inhibitors reverse resistance in epidermal growth factor receptor mutation lung cancer cells with acquired resistance to gefitinib.
    Huang MH, Lee JH, Chang YJ, Tsai HH, Lin YL, Lin AM, Yang JC.
    Mol Oncol; 2013 Feb 07; 7(1):112-20. PubMed ID: 23102728
    [Abstract] [Full Text] [Related]

  • 18. Dual phosphoinositide 3-kinase/mammalian target of rapamycin blockade is an effective radiosensitizing strategy for the treatment of non-small cell lung cancer harboring K-RAS mutations.
    Konstantinidou G, Bey EA, Rabellino A, Schuster K, Maira MS, Gazdar AF, Amici A, Boothman DA, Scaglioni PP.
    Cancer Res; 2009 Oct 01; 69(19):7644-52. PubMed ID: 19789349
    [Abstract] [Full Text] [Related]

  • 19.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 20. Preclinical rationale for PI3K/Akt/mTOR pathway inhibitors as therapy for epidermal growth factor receptor inhibitor-resistant non-small-cell lung cancer.
    Gadgeel SM, Wozniak A.
    Clin Lung Cancer; 2013 Jul 01; 14(4):322-32. PubMed ID: 23332287
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 25.